BioCentury | Jan 12, 2021
Deals

Sanofi joins the myeloid checkpoint movement with Biond deal

...co-stimulatory checkpoint OX40L for inflammatory indications. Its other clinical program also targets a co-stimulatory checkpoint, ICOS...
BioCentury | Jan 11, 2021
Deals

Atopic dermatitis readout drives Sanofi’s $1.1B takeout of Kymab

...which it designs antibodies from transgenic mice. Behind it in the clinic is KY1044, an ICOS-targeting...
...with PD-L1 inhibitor Tecentriq atezolizumab to treat a basket of solid-tumor cancers.Although Sturge acknowledged that ICOS...
BioCentury | Dec 17, 2020
Deals

GSK adds to next-generation checkpoint pipeline with Surface deal

...checkpoints. Its most advanced next generation checkpoint therapy, ICOS...
BioCentury | Nov 2, 2020
Product Development

Next-generation checkpoints take another hit as Jounce stops enrollment in ICOS agonist trial

...Lauren Martz, Senior Editor Jounce’s strategy to re-focus its anti-ICOS mAb program on patients with ICOS-high...
...for continued enrollment.Jounce switched gears to focus on tumor-agnostic development based on biomarkers related to ICOS...
...ICOS are in clinical development. Industry will get a more complete picture of the potential for ICOS...
BioCentury | Oct 9, 2020
Translation in Brief

Philogen immunocytokine for glioma; plus Nordic's radiotherapy, Beth Israel Deaconness, Molecular Partners and Alpine

...modelling acute myeloid leukemia that had been given human peripheral blood mononuclear cells. The dual, inducible ICOS/CD28...
...Inc. Nordic Nanovector ASA Molecular Partners AG Inducible T cell co-stimulator ligand (ICOSLG) (B7-H2) (B7RP1) CD28 Inducible T cell co-stimulator (ICOS) CC...
BioCentury | Sep 1, 2020
Deals

Gilead deal clears path for Jounce to advance immuno-oncology programs

...near-term expenditures are associated with its lead program, anti-ICOS...
...second-line NSCLC patients.Some doubts had arisen about ICOS’s...
BioCentury | Jun 19, 2020
Deals

In second innovative deal this month, AbbVie gains option to Alpine’s ‘first-in-class’ lupus program

...exclusive, worldwide option to license ALPN-101, an Fc fusion protein dual antagonist of CD28 and ICOS...
...Remy Durand, Alpine’s SVP of BD and corporate strategy, told BioCentury that ALPN-101’s dual CD28/ICOS...
...a key co-stimulatory receptor on naïve T cells. Once differentiated into effector T cells, however, ICOS...
BioCentury | Jun 13, 2020
Product Development

Where companies see opportunity in the crowded PD-1 marketplace

...no approved PD-1 inhibitors. An example of the first arm of the strategy is GSK’s ICOS...
...Epidermal growth factor receptor HER2 (EGFR2; ErbB2; neu) - Epidermal growth factor receptor 2 ICOS...
BioCentury | May 23, 2020
Product Development

Hot topics at ASCO 2020

...also make an appearance at the meeting. GSK will present an updated analysis of its ICOS...
...Epidermal growth factor receptor 2 HER3 (ERBB3; EGFR3) - Erb-b2 receptor tyrosine kinase 3 ICOS...
BioCentury | May 23, 2020
Product Development

TIGIT breaks through as next-generation checkpoint target

...but was able to reintroduce it to patients at a lower dose. The immunostimulatory receptor ICOS...
Items per page:
1 - 10 of 627
BioCentury | Jan 12, 2021
Deals

Sanofi joins the myeloid checkpoint movement with Biond deal

...co-stimulatory checkpoint OX40L for inflammatory indications. Its other clinical program also targets a co-stimulatory checkpoint, ICOS...
BioCentury | Jan 11, 2021
Deals

Atopic dermatitis readout drives Sanofi’s $1.1B takeout of Kymab

...which it designs antibodies from transgenic mice. Behind it in the clinic is KY1044, an ICOS-targeting...
...with PD-L1 inhibitor Tecentriq atezolizumab to treat a basket of solid-tumor cancers.Although Sturge acknowledged that ICOS...
BioCentury | Dec 17, 2020
Deals

GSK adds to next-generation checkpoint pipeline with Surface deal

...checkpoints. Its most advanced next generation checkpoint therapy, ICOS...
BioCentury | Nov 2, 2020
Product Development

Next-generation checkpoints take another hit as Jounce stops enrollment in ICOS agonist trial

...Lauren Martz, Senior Editor Jounce’s strategy to re-focus its anti-ICOS mAb program on patients with ICOS-high...
...for continued enrollment.Jounce switched gears to focus on tumor-agnostic development based on biomarkers related to ICOS...
...ICOS are in clinical development. Industry will get a more complete picture of the potential for ICOS...
BioCentury | Oct 9, 2020
Translation in Brief

Philogen immunocytokine for glioma; plus Nordic's radiotherapy, Beth Israel Deaconness, Molecular Partners and Alpine

...modelling acute myeloid leukemia that had been given human peripheral blood mononuclear cells. The dual, inducible ICOS/CD28...
...Inc. Nordic Nanovector ASA Molecular Partners AG Inducible T cell co-stimulator ligand (ICOSLG) (B7-H2) (B7RP1) CD28 Inducible T cell co-stimulator (ICOS) CC...
BioCentury | Sep 1, 2020
Deals

Gilead deal clears path for Jounce to advance immuno-oncology programs

...near-term expenditures are associated with its lead program, anti-ICOS...
...second-line NSCLC patients.Some doubts had arisen about ICOS’s...
BioCentury | Jun 19, 2020
Deals

In second innovative deal this month, AbbVie gains option to Alpine’s ‘first-in-class’ lupus program

...exclusive, worldwide option to license ALPN-101, an Fc fusion protein dual antagonist of CD28 and ICOS...
...Remy Durand, Alpine’s SVP of BD and corporate strategy, told BioCentury that ALPN-101’s dual CD28/ICOS...
...a key co-stimulatory receptor on naïve T cells. Once differentiated into effector T cells, however, ICOS...
BioCentury | Jun 13, 2020
Product Development

Where companies see opportunity in the crowded PD-1 marketplace

...no approved PD-1 inhibitors. An example of the first arm of the strategy is GSK’s ICOS...
...Epidermal growth factor receptor HER2 (EGFR2; ErbB2; neu) - Epidermal growth factor receptor 2 ICOS...
BioCentury | May 23, 2020
Product Development

Hot topics at ASCO 2020

...also make an appearance at the meeting. GSK will present an updated analysis of its ICOS...
...Epidermal growth factor receptor 2 HER3 (ERBB3; EGFR3) - Erb-b2 receptor tyrosine kinase 3 ICOS...
BioCentury | May 23, 2020
Product Development

TIGIT breaks through as next-generation checkpoint target

...but was able to reintroduce it to patients at a lower dose. The immunostimulatory receptor ICOS...
Items per page:
1 - 10 of 627